Geoff Meacham

Merck & Co., Inc. (NYSE: MRK) announced last week the oral COVID-19 pill it is co-developing with Ridgeback Biotherapeutics reduces the risk of hospitalization or death by 50%. The announcement triggered an across-the-board, steep sell-off in COVID-19 vaccine stocks. The Merck Analyst: BofA...

Moderna, Inc. (NASDAQ: MRNA) shares are picking up momentum after a steep sell-off on Monday, triggered by a scientific publication that suggested booster doses are unwarranted at this point of time. The company released a statement Wednesday that said incremental data from the Phase 3 COVE...

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI), an early stage platform technology company that promotes oral dosing with its RaniPill, and RxSight, Inc. (NASDAQ: RXST), an ophthalmology-focused MedTech company, went public in late July. Here's what BofA Securities has to say about the newly...

Moderna, Inc. (NASDAQ: MRNA) shares have rallied since the start of July, rendering the valuation unattractive and "ridiculous," according to a BofA Securities analyst.  The Moderna Analyst: Geoff Meacham maintained an Underperform rating on Moderna with a $115 price target....

A differentiated approach to gene editing has ushered a bullish sentiment from BofA Securities and Morgan Stanley on Graphite Bio, Inc. (NASDAQ: GRPH) just a few weeks after its IPO. BofA Securities on Graphite Bio Analyst Geoff Meacham initiated the firm’s coverage on Graphite with a...

Following the expiry of IPO quiet periods for the recently listed Ambrx Biopharma Inc. (NASDAQ: AMAM), Cyteir Therapeutics, Inc. (NASDAQ: CYT) and Century Therapeutics, Inc. (NASDAQ: IPSC), analysts at BofA Securities initiated coverage of these stocks. The Biopharma Analyst: Analyst Tazeen Ahmad...

The SPDR S&P 500 ETF Trust (NYSE: SPY) is up another 13% so far in the first half of 2021 as investors anticipate a full economic reopening this summer following the COVID-19 pandemic. Unfortunately, the new “delta” strain of the virus is reportedly spreading like wildfire. Bank of...

Biogen Inc. (NASDAQ: BIIB) stock is seeing muted sentiment Tuesday as it emerges from the euphoria over Aduhelm approval, with the most recent trigger being lukewarm data for a partnered program. The Biogen Analyst: Geoff Meacham reiterated a Buy rating on Biogen shares and raised the price...

Moderna, Inc. (NASDAQ: MRNA) shares have been on an extended run since 2020, and with the gains, the stock is already capturing Moderna's pipeline upside, according to a BofA Securities analyst.  The Moderna Analyst: Geoff Meacham maintained an Underperform rating on Moderna with a...

Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over 38%.  The Biogen Analysts: Morgan Stanley analyst Matthew Harrison maintained an Overweight rating on Biogen shares and increased the price target from...

Pfizer Inc. (NYSE: PFE) reported Tuesday with forecast-beating first-quarter earnings and upwardly revised its fiscal year 2021 earnings and revenue guidance. Despite the impressive results, an analyst at BofA Securities is staying on the sidelines of the COVID-19 vaccine stock. The Pfizer...

Inovio Pharmaceuticals, Inc. (NASDAQ: INO), which has fallen behind in the COVID-19 vaccine race, has much to offer beyond a coronavirus vaccine, according to a BofA Securities analyst.  The Inovio Analyst: Geoff Meacham initiated coverage of Inovio with a Neutral rating and $13 price...

Coronavirus vaccine developer Moderna Inc's (NASDAQ: MRNA) stock was moving lower Monday after a downgrade from BofA Securities.  The Moderna Analyst: Geoff Meacham downgraded Moderna shares from Neutral to Underperform and maintained a $150 price target. The Moderna Thesis:...

Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine program is proceeding smoothly, with emergency use authorization likely as soon as late December.  The Moderna Analyst: BofA Securities analyst Geoff Meacham reiterated a Neutral rating on Moderna shares and increased the price target...

Although the details of interim data from the Phase 3 trials of Pfizer Inc’s (NYSE: PFE) COVID-19 vaccine study rea unclear, the results represent “a solid win” for the company, according to BofA Securities. The Pfizer Analyst: Geoff Meacham maintained a Neutral rating on...